Calidi Biotherapeutics, Inc. (CLDI)

USD 1.44

(-16.76%)

Operating Expenses Summary of Calidi Biotherapeutics, Inc.

  • Calidi Biotherapeutics, Inc.'s latest annual operating expenses in 2023 was 28.99 Million USD , up 21.12% from previous year.
  • Calidi Biotherapeutics, Inc.'s latest quarterly operating expenses in 2024 Q2 was 5.39 Million USD , down -9.5% from previous quarter.
  • Calidi Biotherapeutics, Inc. reported a annual operating expenses of 22.89 Million USD in annual operating expenses 2022, up 1185.23% from previous year.
  • Calidi Biotherapeutics, Inc. reported a annual operating expenses of 1.78 Million USD in annual operating expenses 2021, down -73.69% from previous year.
  • Calidi Biotherapeutics, Inc. reported a quarterly operating expenses of 6.37 Million USD for 2024 Q1, down -32.55% from previous quarter.
  • Calidi Biotherapeutics, Inc. reported a quarterly operating expenses of 9.45 Million USD for 2023 Q4, up 32.79% from previous quarter.

Annual Operating Expenses Chart of Calidi Biotherapeutics, Inc. (2023 - 2020)

Historical Annual Operating Expenses of Calidi Biotherapeutics, Inc. (2023 - 2020)

Year Operating Expenses Operating Expenses Growth
2023 28.99 Million USD 21.12%
2022 22.89 Million USD 1185.23%
2021 1.78 Million USD -73.69%
2020 6.77 Million USD 0.0%

Peer Operating Expenses Comparison of Calidi Biotherapeutics, Inc.

Name Operating Expenses Operating Expenses Difference
AIM ImmunoTech Inc. 32.07 Million USD 9.615%
Ampio Pharmaceuticals, Inc. 9.26 Million USD -212.818%
Armata Pharmaceuticals, Inc. 11.64 Million USD -148.88%
Actinium Pharmaceuticals, Inc. 52 Million USD 44.247%
Azitra, Inc. 8.3 Million USD -249.2%
Can-Fite BioPharma Ltd. 8.93 Million USD -224.368%
Chromocell Therapeutics Corporation 6.86 Million USD -322.483%
CEL-SCI Corporation 31.47 Million USD 7.892%
iBio, Inc. 16.85 Million USD -71.967%
Lineage Cell Therapeutics, Inc. 33 Million USD 12.164%
MAIA Biotechnology, Inc. 20.18 Million USD -43.65%
Matinas BioPharma Holdings, Inc. 24.86 Million USD -16.612%
Navidea Biopharmaceuticals, Inc. 13.93 Million USD -108.102%
NovaBay Pharmaceuticals, Inc. 12.89 Million USD -124.779%
NanoViricides, Inc. 8.51 Million USD -240.437%
Oragenics, Inc. 5.45 Million USD -431.773%
BiomX Inc. 26.81 Million USD -8.123%
BiomX Inc. 26.81 Million USD -8.123%
Protalix BioTherapeutics, Inc. 32.05 Million USD 9.547%
Palatin Technologies, Inc. 34.67 Million USD 16.378%
Scorpius Holdings, Inc. 39.81 Million USD 27.185%